Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma

Cohort study (n=69) reports overall response rate of immunotherapy rechallenge was 23%, and reasonably safe with 11 patients (16%) experiencing a grade 3 or higher immune-related adverse event.

Source:

JAMA Oncology